Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
| Autor: | Nikolaos Tsoulos, P. Papakotoulas, George Nasioulas, Evgenia Kapeni, Pinelopi Eleftheria Stamou, Vasiliki Metaxa-Mariatou, Dimitra Ioanna Lampropoulou, George Kesisis, Katerina Tsantikidi, Christos Christodoulou, Dimitrios Petrakis, Georgios N. Tsaousis, Yesim Eralp, Ioannis Boukovinas, Eirini Papadopoulou, Gerasimos Aravantinos, George Pentheroudakis, Flora Stavridi, Ioannis Varthalitis, Nikolaos Katirtzoglou, Anna Koumarianou, Elias Athanasiadis, Athina Kladi-Skandali |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Male Lung Neoplasms Molecular biology Biopsy Mutagenesis and Gene Deletion Techniques Gene Identification and Analysis Cancer Treatment Drug resistance Biochemistry Lung and Intrathoracic Tumors Circulating Tumor DNA 0302 clinical medicine Sequencing techniques Carcinoma Non-Small-Cell Lung Medicine and Health Sciences DNA sequencing Precision Medicine Aged 80 and over Multidisciplinary medicine.diagnostic_test High-Throughput Nucleotide Sequencing Genomics Exons Middle Aged Clinical Practice ErbB Receptors 030220 oncology & carcinogenesis Medicine Female Transcriptome Analysis Research Article Next-Generation Sequencing Adult medicine.medical_specialty Concordance Science Clinical Decision-Making Surgical and Invasive Medical Procedures 03 medical and health sciences Text mining Internal medicine medicine Carcinoma Genetics Biomarkers Tumor Humans Liquid biopsy Mutation Detection Protein Kinase Inhibitors Aged business.industry Liquid Biopsy Biology and Life Sciences Cancers and Neoplasms Computational Biology medicine.disease Genome Analysis Non-Small Cell Lung Cancer respiratory tract diseases Research and analysis methods 030104 developmental biology Molecular biology techniques Mutational Analysis Drug Resistance Neoplasm Mutation Feasibility Studies Molecular Profile Neoplasm Recurrence Local business Biomarkers |
| Zdroj: | PLoS ONE, Vol 14, Iss 12, p e0226853 (2019) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | BackgroundAnalysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and documented form of "liquid biopsy" and provides real-time information on the molecular profile of the tumor without an invasive tissue biopsy.MethodsLiquid biopsy analysis was requested by the referral physician in 121 NSCLC patients at diagnosis and was performed using a sensitive Next Generation Sequencing assay. Additionally, a comparative analysis of NSCLC patients at relapse following EGFR Tyrosine Kinase Inhibitor (TKIs) treatment was performed in 50 patients by both the cobas and NGS platforms.ResultsAt least one mutation was identified in almost 49% of the cases by the NGS approach in NSCLC patients analyzed at diagnosis. In 36 cases with paired tissue available a high concordance of 86.11% was observed for clinically relevant mutations, with a Positive Predictive Value (PPV) of 88.89%. Furthermore, a concordance rate of 82% between cobas and the NGS approach for the EGFR sensitizing mutations (in exons 18, 19, 21) was observed in patients with acquired resistance to EGFR TKIs, while this concordance was 94% for the p.T790M mutation, with NGS being able to detect this mutation in three 3 additional patients.ConclusionsThis study indicates the feasibility of circulating tumor nucleic acids (ctNA) analysis as a tumor biopsy surrogate in clinical practice for NSCLC personalized treatment decision making. The use of new sensitive NGS techniques can reliably detect tumor-derived mutations in liquid biopsy and provide clinically relevant information both before and after targeted treatment in patients with NSCLC. Thus, it could aid physicians in treatment decision making in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |